| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | fanC |
| Uniprot No | P18103 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-181aa |
| 氨基酸序列 | NTGTINFNGKITSATCTIDPEVNGNRTSTIDLGQAAISGHGTVVDFKLKPAPGSNDCLAKTNARIDWSGSMNSLGFNNTASGNTAAKGYHMTLRATNVGNGSGGANINTSFTTAEYTHTSAIQSFNYSAQLKKDDRAPSNGGYKAGVFTTSASFLVTYM |
| 预测分子量 | 32.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组fanC蛋白的示例参考文献(注：以下内容为假设性示例，仅供参考)：
---
1. **《High-yield expression and purification of recombinant fanC protein in E. coli》**
- **作者**: Smith A, et al.
- **摘要**: 研究通过优化大肠杆菌表达系统实现fanC蛋白的高效可溶表达，采用亲和层析纯化，并验证其抗原性，为疫苗开发提供基础。
2. **《Structural insights into fanC adhesin and its role in bacterial biofilm formation》**
- **作者**: Johnson R, et al.
- **摘要**: 通过X射线晶体学解析fanC蛋白的三维结构，揭示其作为粘附素在细菌生物膜形成中的关键作用，为抗感染治疗提供靶点。
3. **《Immunogenicity of recombinant fanC in a murine model of pertussis》**
- **作者**: Lee S, et al.
- **摘要**: 评估重组fanC蛋白作为百日咳疫苗组分的潜力，实验显示其能诱导小鼠产生特异性抗体并增强免疫保护。
4. **《Functional characterization of fanC in iron acquisition pathways of pathogenic bacteria》**
- **作者**: Wang Y, et al.
- **摘要**: 探讨fanC蛋白在病原体铁摄取途径中的功能，发现其与宿主铁结合蛋白相互作用，为抗菌策略提供新方向。
---
如需真实文献，建议通过学术数据库(如PubMed、Web of Science)检索关键词“recombinant fanC protein”或“fanC adhesin”，并筛选相关领域的研究论文。
**Background of FanC Recombinant Protein**
FanC recombinant protein is a genetically engineered version of the FanC antigen, originally derived from *Bordetella pertussis*, the causative agent of whooping cough. FanC is a key component of the bacterium's filamentous hemagglutinin (FHA), a critical virulence factor involved in host cell adhesion and immune evasion. The FHA complex facilitates bacterial attachment to respiratory epithelial cells, enabling colonization and infection.
Recombinant FanC is produced using heterologous expression systems, such as *E. coli* or yeast, to ensure high purity and scalability while eliminating risks associated with native pathogen handling. Its production involves cloning the *fanC* gene into expression vectors, followed by fermentation and purification processes. This approach allows for consistent antigen quality, essential for both research and therapeutic applications.
FanC has garnered attention in vaccine development, particularly as a subunit vaccine candidate against pertussis. Traditional whole-cell pertussis vaccines (wP) contain multiple antigens but may cause side effects, whereas acellular vaccines (aP) use purified components like FHA, pertactin, and pertussis toxin. FanC, as part of FHA, contributes to immune recognition, eliciting antibody responses that neutralize bacterial adhesion. Research also explores its role in diagnostic tools or as a carrier protein in conjugate vaccines.
Despite its potential, challenges remain, including optimizing FanC's stability and immunogenicity. Studies focus on structural modifications or adjuvant combinations to enhance efficacy. Overall, FanC recombinant protein represents a safer, targeted alternative in combating *B. pertussis*, aligning with trends toward precision vaccinology and reduced reactogenicity.
×
